Maurade Gormley

Faculty

Dr. Maurade Gormley

Maurade Gormley

CPNP RN

Assistant Professor/Faculty Fellow

433 First Avenue
New York, NY 10010
United States

Maurade Gormley's additional information

Dr. Gormley is an assistant professor/faculty fellow at NYU Rory Meyers College of Nursing.  Dr. Gormley received her PhD from New York University and MS in nursing with a sub-specialty in oncology from Columbia University. Gormley’s predoctoral training was funded by an NRSA F31 predoctoral fellowship (F31NR017547). Dr. Gormley attended the Summer Genetics Institute at the National Institutes of Health in 2017. Her research focus is psychosocial issues during cancer survivorship, with a focus on fear of cancer recurrence. Her doctoral work explored the association between Oncotype Dx® test results and FCR, health-related quality of life, psychological distress, anxiety, depression, illness representation and perceived risk to better understand the psychosocial response to genomic testing. These findings can be used to better identify individuals at greatest risk of FCR. Dr. Gormley joins NYU Rory Meyers College of Nursing as part of the Provost’s postdoctoral fellowship program.

PHD, NYU Rory Meyers College of Nursing
MSN, Columbia University School of Nursing
BSN, NYU College of Nursing

Faculty Honors Awards

Council for the Advancement of Nursing Science (2017)
Easter Nursing Research Society (2015)
Oncology Nursing Society (2009)
Sigma Theta Tau Nursing Society, Upsilon Chapter (2008)

Publications

Nusinersen versus sham control in infantile-onset spinal muscular atrophy

Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., Farwell, W., De Vivo, D. C., Bradley, W. G., Schroth, M. K., Bodensteriner, J. B., Davis, C. S., Shell, R., Hen, J., Austin, E. D., Aziz-Zaman, S., Cappell, J., Constantinescu, A., Cruz, R., Dastgir, J., Dunaway, S., Engelstad, K., Gormley, M., Holuba La Marca, N., Khandji, A., Kramer, S., Marra, J., Ortiz-Miller, C., Popolizio, M., Salazar, R., Sanabria, L., Weimer, L., Anand, P., Gadeken, R., Golumbek, P. T., Siener, C., Zaidman, C. M., Al-Ghamdi, F., Berde, C., Ghosh, P., Graham, R., Harrington, T., Koka, A., Laine, R., Liew, W., Mirek, E., Ordonez, G., Pasternak, A., Quigley, J., Sethna, N., Souris, M., Szelag, H., Wand, L., Day, J. W., D’Souza, G., Duong, T. T., Gee, R., Kitsuwa-Lowe, J., McFall, D., Patnaik, S., Paulose, S., Perez, J., Proud, C., Purse, B., Ramamurthi, R. J., Sakamuri, S., Sampson, J., Sanjanwala, B., Tesi Rocha, A. C., Watson, K., Welsh, L., Pena, L. D., Case, L., Coates, J., DeArmey, S., Homi, M. M., Milleson, C., Nelson, N., Ross, A., Smith, E., Taicher, B., Wootton, J., Finanger, E., Benjamin, D., Frank, A., Roberts, C., Russman, B., Zilke, K., Berry, D., Civitello, M., Cook, D., Endsley, J. D., Johnson, C., Kasper, M., Leon, W., Lim, A., O’Reardon, K., Sigurdardottir, L. Y., Turner, J., Weber-Guzman, F., Zinn, M., Iannaccone, S. T., Castro, D., Cowie, M., Farrow-Gillespie, A., Herbert, A., Kauk, M., McElroy, D., Miller, N., Nelson, L., Smith, L., Spain, T., Trest, S., Johnson, N., Butterfield, R., DiBella, D., Mayne, K., Newcomb, T. M., Rausch, N., Blomgren, C., Choi, H. W., Epstein, L., Goldman, S., Krosschell, K., Krueger, J., Kurz, J., Rao, V., Parsons, J., Allen, V., Bielsky, A., Booker, K., Camuto, A., Carry, T., Fuhr, P., Gibbons, M., Janas, J., Johnson, H., Kelly, C., Lord-Halvorson, L. S., Nicolarsen, S., Shea, S., Tran, V., VanderVeen, G., Yang, M., Zimmerman, C., Shieh, P., Parziale, N., Rao, L., Said, J. W., Shu, F., Skura, C., Staudt, L., Tennekoon, G., Adang, L., Brandsema, J., Chadehumbe, M., Flickinger, J., Kichula, E., Stanford, D., Toms, M., Zigmont, J., Oskoui, M., Arpin, S., Dinunzio, P., Ingelmo, P. M., Poulin, C., Rivera, G., Sabapathy, C., Srour, M., Turgeon-Desilet, S., Zielinski, D., Selby, K., King, C., Lee, J., Michoulas, A., Roland, E., Vajsar, J., Chau, V., Dowling, J., Haldenby, R., Miki, M., So, S., Pascual Pascual, S. I., Martinez Bermejo, A., Epinosa Garcia, S., Garcia Guixot, S., Martinez Moreno, M. M., Del Pilar Tirado Requero, M., Del Mar Garcia Romero, M., Aguilar, C., Munell Casadesus, F., Gomez Garcia De La Banda, M. B., Gallardo, M., Gili, G., Alavarez Molinero, M., De Los Angeles Tormos Munoz, M., Palacios, N. J., Planas Pascual, B., Del Mar Melendez Plumed, M., Rucian, A. F., Toro Tamargo, E., Gratacos Vinola, M., Borell, S., Eckenweiler, M., Krüger, M., Pechmann, A., Rippberger, B., Stein, S., Vogt, S., Wider, S., Schara, U., Andres, B., Della Marina, A., Ganfuss, A., Jachertz, P., Koelbel, H., Rupprich, K., Schroers, E. S., Sponemann, N., Bruno, C., Fiorillo, C., Garaventa, A., Lanteri, P., Lanzillotta, V., Manzitti, C., Pedermonte, M., Tacchetti, P., Trucco, F., Zuffi, A., De Sanctis, R., Fanelli, L., Luigetti, M., Palermo, C., Pane, M., Piastra, M., Sivo, S., Gargaun, E., Gidaro, T., Gilabert, S., Léger, P. L., Le Moing, A. G., Lilien, C., Mayer, M., Ollievier, Q., Rambaud, J., Taytard, J., Vialle, R., Voit, T., Muntoni, F., D’Argenzio, L., Lister, P., Manzur, A., Pisco Domingos, J., Ramsey, D., Ricotti, V., Schottlaender, L., Scoto, M., Scuplak, S. M., Selby, V., Straub, V., Baily, S., Bertoli, M., Mayhew, A. G., Lofra, R. M., Murphy, A., Wood, C., Darin, N., Eldblom, J., Kimber, E., Kroksmark, A. K., Lindstedt, A., Michael, E., Sofou, K., Deconinck, N., Christiaens, A., Coppens, S., DeCock, K., De Vos Voor, E., Dorban, F., Gilbert, G., Rooze, S., Tahon, V., Van Coster, R., Van Der Looven, R., Vanlander, A., Vens, D., Verhelst, H., Wenderickx, B., Wittevrongel, S., Farrar, M., Berthon-Jones, N., Doumit, M. A., Herbert, K. J., Kandula, T., Morrison, M., O’Brien, J., Richardson, S., Ferreira Sampaio, H. A., Teoh, H. L., Ryan, M., Carroll, K. M., De Valle, K. L., Villano, D., Woodcock, I., Yiu, E. M., Ardicli, D., Gunbey, C., Haliloglu, V. G., Karaduman, A. A., Konuskan, B., Yildiz Sarikaya, F. G., Serdaroglu, E., Tanyildiz, M., Temucin, C. M., Yildirim, M., Yilmaz, O. T., Arakawa, R., Chiba, Y., Eto, K., Hirasawa, K., Ikai, T., Ito, S., Ito, Y., Kaburagi, Y., Kaneko, H., Matsumaru, S., Matsushima, N., Mizuochi, K., Nagata, S., Nakatsukasa, H., Nishikawa, A., Otani, Y., Sato, T., Shichiji, M., Sugimoto, K., Takeshita, A., Yanagishita, T., Yamauchi, A., Takeshima, Y., Fujino, T., Fukuda, N., Lee, T., Oriyama, K., Shibano, T., Shimomura, H., Tachikawa, T., Tanaka, Y., Taniguchi, N., Chae, J. H., Choi, S. A., Chun, S. M., Jo, H., Kim, H., Kim, S. Y., Lee, J. S., Lim, B. C., Shin, H. I., Son, W. S., Chan, S., Chung, A. C., Yan, C. S., Stella, C., Joseph, C. K., Ng, C. S., Alvin, H. C., Janice, I. J., Wendy, L. W., Chui-San, M. N., Ki, N. Y., Shun, T. N., Connie, W. Y., Virginia, W. C., Yvonne, Y., Jong, Y. J., Chen, T. H., Chou, P. C., Chou, Y. H., Chung, H. W., Hsu, J. H., Ju, Y. H., Liang, W. C., Shih, H. H., Wang, H. Y., Wu, Y. C., & Zeng, Y. S. (2017). New England Journal of Medicine, 377(18), 1723-1732. 10.1056/NEJMoa1702752
Abstract
Abstract
BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. METHODS: We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis. RESULTS: In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS: Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.

Respiratory management of spinal muscular atrophy type 2

Gormley, M. C. (2014). Journal of Neuroscience Nursing, 46(6), E33-E41. 10.1097/JNN.0000000000000080
Abstract
Abstract
Respiratory insufficiency is the primary cause of morbidity and mortality among patients with spinal muscular atrophy type 2. The primary complications include ineffective cough with decreased airway clearance, nocturnal hypoventilation, diminished lung and chest wall development, and increased risk for pulmonary infection. Respiratory devices including mechanical insufflator-exsufflator and bilevel positive airway pressure are the primary devices of respiratory maintenance and treatment and are associated with decreased morbidity and fewer hospital admissions. This article discusses the primary respiratory complications of spinal muscular atrophy type 2 and the role of respiratory interventions to promote growth and development, improve cough efficacy, reverse nocturnal hypoventilation, and prevent and treat pulmonary infection.